Search results for "oncogene"

showing 10 items of 1005 documents

Catalase-independent early-gene expression in rat brain following acute ethanol exposure

2004

Early-gene expression evoked by acute ethanol treatment was studied in rat brain by quantitative immunocytochemistry, with reference to ethanol metabolism by the enzyme catalase. Colocalization with mu-opioid receptor (MOR) sites was also examined. Ethanol challenges [1, 2.5, and 4 g/kg intraperitoneally (i.p.)] evoked dose-dependent increases in c-Fos expression in several brain regions, but overlap with MOR-rich sites was only partial. Strong inhibition of brain catalase activity (ca. 60%) with 3-amino-1,2,4-triazole (AT, 1 g/kg i.p.) did not alter ethanol-induced c-Fos nor Krox-24 expression in any of the brain regions analyzed. This evidence demonstrates that catalase-mediated metabolis…

MaleNervous systemmedicine.medical_specialtyCentral nervous systemReceptors Opioid muGene ExpressionCell Countc-FosRats Sprague-DawleyInternal medicinemedicineAnimalsEnzyme InhibitorsEthanol metabolismMolecular BiologyAmitroleBrain ChemistryEthanolbiologyGeneral NeuroscienceBrainCentral Nervous System DepressantsColocalizationCatalaseImmunohistochemistryRatsmedicine.anatomical_structureEndocrinologyCatalasebiology.proteinNeurology (clinical)μ-opioid receptorProto-Oncogene Proteins c-fosImmediate early geneDevelopmental BiologyBrain Research
researchProduct

Expression of Fos in the piriform cortex after acquisition of olfactory learning: An immunohistochemical study in the rat

2001

The piriform cortex (PCx), the main area of the primary olfactory cortex, is assumed to play a role in olfactory memory. Involvement of this paleocortex in mnesic processes was investigated by using Fos immunocytochemistry after acquisition of a two-odor discrimination task. Trained rats had to associate one odor of a pair with water reward while pseudo-trained rats were randomly rewarded. We further used non-trained rats and home cage control animals to determine the effect of manipulation and basal Fos level respectively. Except in control rats, Fos immunoreactivity was mainly distributed in brain areas involved in olfactory processing, learning and arousal. The trained, pseudo-trained, a…

MaleNeuronsOlfactory systemBehavior AnimalGeneral NeuroscienceCentral nervous systemImmunocytochemistryOlfactory PathwaysOlfactionImmunohistochemistryRatsDiscrimination LearningSmellPrimary olfactory cortexmedicine.anatomical_structurePiriform cortexmedicineAnimalsConditioning OperantRats WistarOlfactory LearningOlfactory memoryPsychologyProto-Oncogene Proteins c-fosNeuroscienceBrain Research Bulletin
researchProduct

No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs

2001

The oxygen deficiency seen in solid tumors is predominantly caused by an insufficient O2 supply as a result of inadequate tumor perfusion. The aim of this study was to analyze whether a number of vasodilator drugs might be suitable to increase tumor perfusion and consequently improve the oxygenation status of experimental tumors. Rats with s.c. DS-sarcomas were treated with either Na+-nitroprusside (7-25 microg x min(-1) x kg(-1) BW) or nifedipine (10 microg x min(-1) x kg(-1) BW). Red blood cell (RBC) flux was assessed continuously using laser-Doppler flowmetry and mean tumor pO2 was measured polarographically using O2-sensitive catheter electrodes. Systemic application of the vasodilator …

MaleNitroprussideCancer Researchmedicine.medical_specialtyNifedipineVasodilator AgentsRats Sprague-DawleyNifedipineInternal medicineLaser-Doppler FlowmetrymedicineAnimalsInfusions IntravenousOncogenebusiness.industryOxygenationLaser Doppler velocimetryRatsOxygenRed blood cellmedicine.anatomical_structureEndocrinologyOncologyRegional Blood FlowCardiologyVascular resistanceSarcoma ExperimentalSodium nitroprussidebusinessPerfusionmedicine.drugInternational Journal of Oncology
researchProduct

The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and con…

2009

Benztropine (BZT) analogs, a family of high-affinity dopamine transporter ligands, are molecules that exhibit pharmacological and behavioral characteristics predictive of significant therapeutic potential in cocaine addiction. Here, we examined in mice the effects of 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane (AHN-1055) on motor activity, conditioned place preference (CPP) and c-Fos expression in the striatum. AHN-1055 produced mild attenuation of spontaneous locomotor activity at a low dose (1 mg/kg) and weak stimulation at a higher dose (10 mg/kg). In parallel, the BZT analog significantly increased c-Fos expression in the dorsolateral caudoputamen at the high dose, whereas producing ma…

MaleNomifensineConditioning ClassicalAHN-1055cocaineGene ExpressionStimulationStriatumBZT derivativeNucleus accumbensPharmacologyplace preferenceMotor ActivityCocaine-Related DisordersMiceCocaineDopamine Uptake InhibitorsRewardDopaminemedicineAnimalsDopamine transporterPharmacologyBenztropinec-FosbiologyDose-Response Relationship DrugChemistryVentral striatumBrainConditioned place preferencePsychiatry and Mental healthNomifensinemedicine.anatomical_structureSpace Perceptionbiology.proteinStereotyped Behaviorlocomotor activityNeuroscienceProto-Oncogene Proteins c-fosmedicine.drugNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Brain processing of the mammary pheromone in newborn rabbits.

2011

International audience; Chemosignals strongly contribute to social interactions in mammals, including mother-young relationships. In the European rabbit, a volatile compound emitted by lactating females in milk, the 2-methylbut-2-enal, has been isolated. Carrying the properties of a pheromone, in particular the spontaneous ability to release critical sucking-related movements in newborns, it has been called the mammary pheromone (MP). Lesion of the vomeronasal organ and preliminary 2-deoxyglucose data suggested that the MP could be processed by the main olfactory system. However, the neuronal substrate that sustains the MP-induced response of neonates remained unknown. Here, we evaluated Fo…

MaleOlfactory systemVomeronasal organ[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH: NeuronsMESH: RabbitsPheromonesMESH : PheromonesMESH: Animals NewbornThirstMESH: Vomeronasal OrganBehavioral Neuroscience0302 clinical medicinePiriform cortexMESH : HabenulaMESH : FemaleMESH: AnimalsMESH : Olfactory BulbNeurons0303 health sciencesMESH: PheromonesLamina terminalisMESH: Proto-Oncogene Proteins c-fosMESH : Animals NewbornOlfactory PathwaysOlfactory BulbHabenulamedicine.anatomical_structureMESH: HabenulaPheromoneFemaleRabbitsVomeronasal Organmedicine.symptomProto-Oncogene Proteins c-fosMESH: Olfactory Bulbmedicine.medical_specialtyMESH : HypothalamusMESH : Vomeronasal OrganMESH : MaleHypothalamusBiologyMESH : Neurons03 medical and health sciencesInternal medicinemedicineAnimalsMESH : Rabbits030304 developmental biologyHabenulaMESH : Olfactory PathwaysNewbornMESH: HypothalamusMESH: MaleOlfactory bulbEndocrinologyMESH : Proto-Oncogene Proteins c-fosAnimals NewbornMESH : AnimalsMESH: Female[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryMESH: Olfactory Pathways
researchProduct

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

MaleOncogene Proteins Fusionmedicine.medical_treatmentDrug ResistancePhases of clinical researchSalvage therapyKaplan-Meier EstimatePharmacologyGastroenterologyBenzoatesArsenicalschemistry.chemical_compoundLeukemia Promyelocytic AcuteRecurrenceAntineoplastic Combined Chemotherapy ProtocolsMedicineArsenic trioxidePromyelocyticOncogene ProteinsTumorLeukemiaRemission InductionHematopoietic Stem Cell TransplantationCell DifferentiationOxidesclinical trialHematologyMiddle AgedCombined Modality Therapyall-trans retinoic acidarsenic trioxideLeukemiaCardiovascular DiseasesFemalemedicine.drugAdultmedicine.medical_specialtyTetrahydronaphthalenesAcute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; clinical trial; tamibarotene; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia Promyelocytic Acute; Male; Middle Aged; Oncogene Proteins Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; TretinoinAntineoplastic AgentsTretinoinAcuteArticleDisease-Free SurvivalTretinoinInternal medicineBiomarkers TumorHumansFusionneoplasmsAgedFebrile NeutropeniaSalvage TherapyChemotherapybusiness.industrymedicine.diseasetamibaroteneAcute promyelocytic leukaemiaConsolidation ChemotherapychemistryDrug Resistance NeoplasmNeoplasmTamibarotenebusinessSettore MED/15 - Malattie del SangueFebrile neutropeniaBiomarkers
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct

Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

2011

Abstract Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through pharmacologic stabilization or geneti…

MaleOncologyCancer Researchmedicine.medical_specialtyEpithelial-Mesenchymal TransitionMice TransgenicAdenocarcinomaBiologymedicine.disease_causeCell DegranulationMiceProstate cancerProstateCell Line TumorInternal medicineTumor MicroenvironmentmedicineMast CellAnimalsHumansMast CellsReceptors Tumor Necrosis Factor Member 25Tumor microenvironmentAdenocarcinoma; Animals; Carcinoma Neuroendocrine; Cell Degranulation; Cell Line Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice Inbred C57BL; Mice Transgenic; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Receptors Tumor Necrosis Factor Member 25; Tumor Microenvironment; Cancer Research; OncologyAnimalProstatic NeoplasmsCancermedicine.diseasehumanitiesCarcinoma NeuroendocrineMice Inbred C57BLProto-Oncogene Proteins c-kitmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyTumor progressionProstatic NeoplasmDisease ProgressionAdenocarcinomaCarcinogenesisHumanTramp
researchProduct

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-sm…

2015

Background: This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. Patients and methods: Patients with one prior systemic therapy for advanced disease were eligible. Docetaxel (75 mg/m<sup>2</sup> on day 1) was administered alone or with ganetespib (150 mg/m<sup>2</sup> on days 1 and 15) every 3 weeks. The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS). Resul…

MaleOncologyHSP90 inhibitormedicine.medical_specialtyLung NeoplasmsPopulationGanetespibPhases of clinical researchDocetaxelAdenocarcinomaNeutropeniaDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Carcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHSP90 Heat-Shock ProteinsLung cancereducationAgedProportional Hazards Modelseducation.field_of_studyL-Lactate Dehydrogenasebusiness.industryHazard ratioHematologyMiddle AgedTriazolesmedicine.diseaseTreatment OutcomeAdvanced NSCLCOncologyDocetaxelGanetespibAdenocarcinomaFemaleTaxoidsbusinessmedicine.drugAnnals of Oncology
researchProduct

Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Grupp…

2005

BACKGROUND: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance in terms of disease relapse and overall survival has not yet clearly been established. PATIENTS AND METHODS: A prospective study was carried out on paired tumor and normal colon tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective surgery for primary operable sporadic CRC. Mutations within the TP53 (exons 5-8) and Ki-ras (exon 2) genes were detected by PCR-SSCP analyses following sequencing. RESULTS: Mutation analyses of exons 5 to 8 of the TP53 gene showe…

MaleOncologyMultivariate analysisColorectal cancerpolymerase chain reactionmedicine.medical_treatmentLeucovorinColorectal Neoplasmmedicine.disease_causeBioinformaticsExonAntineoplastic Combined Chemotherapy ProtocolsProspective Studiesexongene mutationmultivariate analysiProspective cohort studysingle strand conformation polymorphism MeSH: Adenocarcinomaprotein p53 EMTREE medical terms: adultProto-Oncogene ProteinMutationarticleprotein domainclinical trialHematologyMiddle AgedagedItalypriority journalOncologyChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemaleFluorouracilColorectal Neoplasmscancer tissueprognosiprospective studyHumansamplingmedicine.medical_specialtyfolinic acidgene sequenceAdenocarcinomarectum carcinomaProto-Oncogene Proteins p21(ras)outcomes researchProto-Oncogene ProteinsInternal medicinemedicineHumanscontrolled studyneoplasmsGeneNeoplasm StagingChemotherapyEMTREE drug terms: fluorouracillevamisoleAntineoplastic Combined Chemotherapy Protocolcontrolled clinical trialbusiness.industryfluorouracil; folinic acid; K ras protein; levamisole; protein p53 adult; aged; article; cancer tissue; clinical trial; codon; colon adenocarcinoma; colorectal surgery; controlled clinical trial; controlled study; exon; gene mutation; gene sequence; human; human cell; human tissue; Italy; major clinical study; male; multivariate analysis; oncology; outcomes research; polymerase chain reaction; prediction; priority journal; prognosis; prospective study; protein domain; rectum carcinoma; sampling; sequence analysis; single strand conformation polymorphism Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Levamisole; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Prospective Studies; Proto-Oncogene Proteins; ras Proteins; Tumor Suppressor Protein p53 [EMTREE drug terms]human cellLymphatic Metastasipredictionras Proteinmedicine.diseasemajor clinical studyhuman tissueProto-Oncogene Proteins p21(ras)K ras proteinProspective Studiecolon adenocarcinomaMultivariate AnalysisMutationras Proteinscolorectal surgerysequence analysicodonTumor Suppressor Protein p53businessAnnals of Oncology
researchProduct